Protocol Ledger

NCT05037760 · Phase II · RECRUITING

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

Interventional Phase II clinical trial protocol NCT05037760 sponsored by Takeda in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-16 Enrollment: 135 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05037760
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)135 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05037760
Protocol FieldVerified Registry Value
NCT IdentifierNCT05037760
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment135 participants (ESTIMATED)
Registered Start Date2021-12-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05037760
Hospital Research SiteLocationSite Profile
Hospital de Clinicas de Porto AlegrePorto Alegre, BrazilOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI